[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"stem-cell-transplant\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:stem-cell-transplant":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,45,70,94,122,149,177,205,232,277],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100601182","psychosocial-and-behavioral-intervention-for-stem-cell-transplant-patients-and-their-family-caregivers-100601182",false,"NCT07107165","Psychosocial and Behavioral Intervention for Stem Cell Transplant Patients and Their Family Caregivers","Adapting After Discharge From Allogeneic SCT: Partnering Together; Dyadic Intervention to Improve Patient-Family Caregiver Team-Based Management of the Medical Regimen After Allogeneic Hematopoietic Cell Transplantation","Inclusion Criteria:\n\n* Patient undergoing a stem cell transplant at the University of Pittsburgh Hillman Cancer Center\n* 18 years or older\n* having a family caregiver age 18 years or older also willing to participate in the study\n* willing to accept randomization\n\nExclusion Criteria:\n\n* Prior history of stem cell transplant\n* Non-English speaking","ALL","18 Years",{"count":19,"type":20},208,"ESTIMATED","INTERVENTIONAL",[23],"NA","Adherence to the medical regimen after stem cell transplant is challenging for both patients and their family caregivers. The investigators propose a randomized clinical trial testing two brief psychosocial interventions to determine if either improves patient and family caregiver psychosocial and health-related outcomes.",[26,27,28],"Stem Cell Transplant","Hematopoetic Stem Cell Transplant","Hematopoetic Stem Cell Transplantation",[30,31],"stem cell transplant","hematopoietic stem cell transplant","RECRUITING","2026-03-26",{"date":35,"type":36},"2026-04-01","ACTUAL",{"date":38,"type":36},"2025-07-01",{"date":40,"type":20},"2027-07",{"name":42,"class":43},"University of Pittsburgh","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":21,"phases":56,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":44},"100498858","phase-2-shingrix-in-recipients-of-allogeneic-transplants-100498858","NCT05775718","Shingrix In Recipients of Allogeneic Transplants","Safety and Immunogenicity of Shingrix Administered to Recipients of Allogeneic Peripheral and Cord Blood Stem Cell Transplants: Effect of Timing of Vaccination After Transplantation","Allo","Inclusion Criteria:\n\n* Allo-SCT recipients being age 18 - 79 years at time of allo-SCT.\n* Written informed consent being obtained from the subject\n* Two doses of RZV, separated by 2 to 6 months, administered at least 1 year after allo-SCT.\n* Enrollment at \\>\u002F= 18 months after second dose of Shingrix.\n* Female subjects of childbearing potential (FOCBP) enrolled in the study only if they:\n\n  * have practiced adequate contraception for 30 days prior to vaccination with any dose of zoster vaccine and\n  * have a negative pregnancy test on the day of each dose of zoster vaccine and\n  * agree to continue adequate contraception during the vaccination period and for 2 months after receipt of the vaccine.\n* Investigator belief that the participant will comply with the requirements of the protocol\n\nExclusion Criteria:\n\n* Active Graft Versus Host Disease (aGVHD) at the time of enrollment and receipt of the third dose of RZV\n* Having received ≥20 mg prednisone for more than 2 weeks (or equivalent) in the 8 weeks preceding enrollment.\n* Receiving any significant immunosuppressive therapy other than for graft maintenance, in the opinion of the investigator.\n* Having received a live attenuated vaccine within the last 4 weeks, or inactivated vaccine in the last 2 weeks, prior to enrollment.\n* Having a history of HZ after the administration of the primary 2-dose RZV immunization regimen.\n* Pregnancy or breastfeeding\n* Receiving investigational drugs from 30 day before enrollment or planned during the study\n* Inability of participants unable to comply with the study schedule in the opinion of the investigator","79 Years",{"count":55,"type":20},55,[57],"PHASE2","This research is designed to determine if the adjuvanted recombinant glycoprotein E (gE) herpes zoster (HZ) vaccine (Shingrix) has acceptable immunogenicity and safety in people who have undergone allogeneic stem cell transplant (allo-SCT). Specifically, it will determine the effect of the interval after transplantation on the immune response and if an additional dose of vaccine is needed to improve the vaccine-induced responses.",[60,26],"Bone Marrow Transplant","2026-02-02",{"date":63,"type":36},"2026-02-05",{"date":65,"type":36},"2023-10-24",{"date":67,"type":20},"2030-12-01",{"name":69,"class":43},"University of Colorado, Denver",{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":74,"acronym":4,"eligibilityCriteria":75,"healthyVolunteers":76,"sex":16,"minAge":77,"maxAge":78,"enrollmentInfo":79,"targetDuration":4,"studyType":21,"phases":81,"briefSummary":82,"conditions":83,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":44},"100439067","behavioral-weight-loss-intervention-utilizing-mobile-health-technology-in-hematopoietic-stem-cell-transplant-patients-100439067","NCT04997473","Behavioral Weight Loss Intervention Utilizing Mobile Health Technology in Hematopoietic Stem Cell Transplant Patients","Inclusion Criteria:\n\n* Patients ≥ 13 and ≤ 30 years old with a history of HSCT of any type, at least 100 days post-transplant at initial consultation of the study, will be eligible for the study.\n* Both male and female patients will be eligible.\n* Patients must classify as obese, represented as Body mass index \\[BMI\\] ≥85th percentile for age and gender.\n* Patients must also be able to read English since the app intervention is only available in English form.\n\nExclusion Criteria:\n\n* Patients who are ≤ 13 or ≥ 30 years old are not eligible for the study.\n* Patients who are \\\u003C 100 days post-transplant at initial consultation will not be eligible for the study, but may become eligible if they are \\>100 days post-transplant at their next consultation that falls within the enrollment window.\n* Patients whose BMI does not fall under the obese category will be excluded.\n* No patients will be excluded for any specific underlying medical condition, but decisions will be made on a case by case basis if a patient's functioning is deemed to significantly interfere with intervention participation.",true,"13 Years","30 Years",{"count":80,"type":20},20,[23],"Pilot study enrolling obese post HSCT (hematopoietic stem cell transplantation) patients at the hematology\u002Foncology clinic at the Mattel Children's Hospital, University of California, Los Angeles. Parameters include percent over the 95th percentile (%BMIp95), zBMI, fasting metabolic metrics, addictive eating habits, and motivation for change.",[84,26],"Obesity","2026-01-26",{"date":87,"type":36},"2026-01-28",{"date":89,"type":36},"2021-08-15",{"date":91,"type":20},"2027-01-09",{"name":93,"class":43},"University of California, Los Angeles",{"id":95,"slug":96,"hasResults":11,"nctId":97,"briefTitle":98,"officialTitle":99,"acronym":4,"eligibilityCriteria":100,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":101,"enrollmentInfo":102,"targetDuration":4,"studyType":21,"phases":104,"briefSummary":106,"conditions":107,"keywords":4,"overallStatus":112,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":44},"100620482","early-phase-1-addition-of-venetoclax-to-combined-hematopoietic-stem-cell-and-kidney-transplantation-100620482","NCT07358195","Addition of Venetoclax to Combined Hematopoietic Stem Cell and Kidney Transplantation","Addition of Venetoclax to Combined Reduced Intensity Hematopoietic Stem Cell and Kidney Transplantation for Patients With Chronic Kidney Disease and Hematologic Malignancy","Recipient Inclusion Criteria:\n\n* Patient ages 18-70\n* Underlying hematological malignancy which is deemed as being potentially curable with allogeneic bone marrow or PBSC transplantation by the BMT voting team.\n* Hematological malignancies include, but are not limited to: acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myelogenous leukemia (CML), chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma (NHL), Hodgkin lymphoma, multiple myeloma (MM), myelodysplastic syndrome (MDS. Patient should be in a partial (PR) or complete remission (CR) at the time of the transplant.\n* Existence of an HLA-matched or haploidentical relative who passes standard donor evaluations for bone marrow and kidney donation\n* LVEF \\> 40% as measured by echocardiography or MUGA\n* FEV1, FVC, and DLCO \\> 50% of predicted as measured by standard PFTs\n* Total bilirubin \\\u003C 2.0 (unless diagnosis of Gilbert's or hemolysis is made) and AST, ALT, alkaline phosphatase all \\\u003C 5x institutions upper limit of normal\n* ABO compatibility in the host vs. graft direction\n* Men and women of reproductive potential must agree to use a reliable method of birth control during the treatment, and women should do so for a period of 1 year following the transplant.\n* Participants should be on dialysis or have a CrCl ≤ 35 ml\u002Fmin\n* Life expectancy greater than 6 months\n* Recipient ability to understand and provide informed consent\n\nDonor Inclusion Criteria:\n\n* HLA matched or haploidentical relative as defined by 3\u002F6, 4\u002F6, or 5\u002F6 HLA-matched at HLA -A, -B, or -DRB1 who is 18-70 years of age\n* ECOG performance status 0 or 1\n* Excellent health per conventional pre-donor history (medical and psychosocial evaluation)\n\n  • Acceptable laboratory parameters (hematology in normal or near-normal range; liver function \\\u003C 3 times the upper limit of normal and normal creatinine)\n* Compatible ABO blood group\n* Negative donor lymphocyte cross match\n* No positive testing for active viral infection (Hepatitis B, Hepatitis C, HIV)\n* Donor ability to understand and provide informed consent\n* Meets standard institutional criteria for both bone marrow or peripheral blood stem cell (PBSC) and kidney donation\n\nExclusion Criteria:\n\n* Active serious infection\n* Participation in other investigational drug use at the time of enrollment\n* Positivity for active infection with HIV, HCV, or HBV\n* ABO blood group incompatibility in the host-vs-graft direction","70 Years",{"count":103,"type":20},3,[105],"EARLY_PHASE1","The primary objective is to assess the safety of the addition of venetoclax to reduced intensity conditioning for HLA-matched and haploidentical combined HSC and kidney transplantation as measured by stable full donor hematopoiesis and absence of CTCAE grade IV or V toxicity attributable to venetoclax.",[108,26,109,110,111],"Kidney Failure Chronic","Stem Cell Transplant Complications","Tolerance","Hematologic Cancer","NOT_YET_RECRUITING","2026-01-13",{"date":115,"type":36},"2026-01-22",{"date":117,"type":20},"2026-07",{"date":119,"type":20},"2029-12",{"name":121,"class":43},"Massachusetts General Hospital",{"id":123,"slug":124,"hasResults":11,"nctId":125,"briefTitle":126,"officialTitle":126,"acronym":127,"eligibilityCriteria":128,"healthyVolunteers":11,"sex":16,"minAge":129,"maxAge":130,"enrollmentInfo":131,"targetDuration":4,"studyType":21,"phases":133,"briefSummary":135,"conditions":136,"keywords":4,"overallStatus":112,"whyStopped":4,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":140,"startDateStruct":142,"completionDateStruct":144,"leadSponsor":146,"locationsCount":148},"100615846","phase-2-framework-for-optimizing-refining-and-unifying-management-of-hsct-in-pediatric-all-100615846","NCT07297914","Framework for Optimizing, Refining, and Unifying Management of HSCT in Pediatric ALL","FORUM2","Inclusion criteria applicable to all substudies\n\n* Male and female patients with allogenic transplant indication for ALL, as determined by national frontline protocols\n* Age ≥3 months to ≤25 years at the time of HSCT.\n* Patients must be in complete remission (with \\\u003C5% blasts and absence of leukemia cells in extramedullary sites) prior to undergoing HSCT.\n* Selected donor must be either a matched donor (matched donor category includes 9\u002F10 identical siblings and 10\u002F10 or 9\u002F10 HLA-matched unrelated donors) or a mismatched family donor (≤8\u002F10 HLA match). Either bone marrow or peripheral blood stem cell grafts are permitted. Cord blood is permitted, as well, provided that the unit is at least 6\u002F8 HLA matched and with a cryopreserved cellularity of at least 3x107 nucleated cells\u002FKg recipient body weight.\n* Female patients of childbearing potential must have a negative pregnancy test at screening, and all patients must agree to adhere to effective contraception during the study period.\n* Written study informed consent and\u002For assent from the patient and\u002For the parent, or guardian\n\nExclusion criteria applicable to all substudies\n\n* Patients \\\u003C 3 months and \\> 25 years of age at the time of HSCT.\n* Patients not in complete morphological remission at the time of enrollment.\n* Patients with an initial diagnosis of Non-Hodgkin Lymphoma (NHL).\n* Patients with ALL as a secondary malignancy.\n* Patients with a history of previous autologous or allogeneic HSCT (prior allogeneic transplantation is permitted for subjects receiving post-transplant interventions, such as those enrolled in the R2 and P1 substudies, provided that this is their first allogeneic HSCT).\n* Female patients who are pregnant or breast feeding.\n* Fertile male or female patients of childbearing potential who do not agree to abstinence or, if sexually active, do not agree to the use of contraception.\n* Active clinically uncontrolled bacterial, fungal, parasitic, or viral infection. Infections are considered controlled if appropriate therapy has been instituted and, at the time of screening, no physical or radiographic signs of infection progression are present.\n* Active HBV or HCV infection that requires treatment, or at risk for HBV reactivation (e.g. positive HBsAg). Subjects with negative HbsAg and positive total HB core antibody may be included if HBV DNA is undetectable at the time of screening. Subjects who are positive for HCV antibody are eligible only if polymerase chain reaction test is negative for HCV RNA. Subjects whose immune status is unknown or uncertain must have results confirming immune status before enrollment. Prior serology results are acceptable for determining eligibility.\n* Known human immunodeficiency virus infection (HIV).\n* Significant respiratory disease including patients who are on mechanical ventilation or who have resting O2 saturation \\\u003C90% by pulse-oximetry on room-air.\n* Presence of severely impaired renal function (confirmed within 72 hours prior to study treatment start) defined by:\n* Glomerular Filtration Rate (GFR) \\\u003C 30 mL\u002Fmin\u002F1.73 m2 using estimated creatinine clearance calculated by updated bedside Schwartz equation or Cockcroft Gault equation OR\n* Renal dialysis requirement\n* Clinically significant or uncontrolled cardiac disease including any of the following:\n* Uncontrolled hypertension\n* New York Heart Association Class III or IV congestive heart failure\n* Clinically significant cardiac arrhythmias\n* Severe hepatic insufficiency, defined by any of the following:\n* Child-Pugh Class C liver disease\n* AST (aspartate aminotransferase) or ALT (alanine aminotransferase) levels \\> 5 times the upper limit of normal (ULN), unless attributable to GvHD\n* Total bilirubin \\> 3.0 mg\u002FdL, unless attributable to GvHD\n* INR (International Normalized Ratio) ≥ 1.7\n* Clinical evidence of hepatic encephalopathy or ascites\n* Presence of severe concomitant constitutional disease that precludes treatment as per protocol, based on the investigator's judgment. Examples include but are not limited to: Down syndrome with severe comorbidities, significant cardiac malformations, and metabolic disorders affecting treatment feasibility.\n* Underlying or current medical or psychiatric condition that, in the opinion of the Investigator, would interfere participation in the study, pose a significant risk to the patient or interfere with interpretation of study data.\n* Karnofsky or Lansky performance score \\\u003C50%, indicating significant functional impairment.\n* Patients who are unwilling or unable to comply with study procedures, including follow-up requirements and treatment schedules.","3 Months","25 Years",{"count":132,"type":20},1000,[57,134],"PHASE3","Current therapeutic strategies for high-risk or relapsed ALL patients often involve intensive treatments, including allogeneic hematopoietic stem cell transplantation (HSCT). HSCT remains a cornerstone of therapy, offering curative potential; however, it is associated with considerable risks, including non-relapse mortality (NRM), significant morbidity, and long-term complications that continue to be major concerns.\n\nIn response to these challenges, the FORUM consortium has made substantial progress in improving outcomes for children with ALL undergoing HSCT. The consortium focuses on reducing life-threatening and lifelong complications, ultimately aiming to enhance quality of life for these high-risk patients. Building on the robust evidence generated by FORUM1, the FORUM2 study has been designed to further optimize the role of HSCT in ALL across all age groups and donor settings within a harmonized and internationally coordinated framework.\n\nThe FORUM2 study introduces a master protocol structure that encompasses multiple hypothesis-driven substudies, each addressing a specific determinant of HSCT outcomes. This design enables simultaneous or sequential evaluation of novel strategies while ensuring uniform governance, endpoint definitions, and data-quality standards. The overarching objective is to refine the role of HSCT in ALL by reducing treatment-related toxicity while preserving the essential graft-versus-leukemia effect.",[137,26,138],"Acute Lymphoblastic Leukemia (ALL)","Graft -Versus-host-disease","2025-12-17",{"date":141,"type":36},"2025-12-22",{"date":143,"type":20},"2026-01-15",{"date":145,"type":20},"2032-12-01",{"name":147,"class":43},"Bambino Gesù Hospital and Research Institute",9,{"id":150,"slug":151,"hasResults":11,"nctId":152,"briefTitle":153,"officialTitle":154,"acronym":155,"eligibilityCriteria":156,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":101,"enrollmentInfo":157,"targetDuration":4,"studyType":21,"phases":159,"briefSummary":160,"conditions":161,"keywords":163,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":167,"lastUpdatePostDateStruct":168,"startDateStruct":170,"completionDateStruct":172,"leadSponsor":174,"locationsCount":176},"100147379","ex-vivo-t-cell-depletion-of-mobilized-peripheral-blood-stem-cells-via-cd34-selection-100147379","NCT01189786","Ex Vivo T-Cell Depletion of Mobilized Peripheral Blood Stem Cells Via CD34-Selection","Ex Vivo T-Cell Depletion of Mobilized Peripheral Blood Stem Cells Via CD34-Selection (EXCESS)","EXCESS","Inclusion criteria for Stem Cell Transplant WITH Conditioning (COHORT 1)\n\n1. Patient requiring allogeneic SCT\n2. Age between birth and 70 years\n3. Patient and\u002For responsible person able to understand and sign consent\n\nExclusion criteria for Stem Cell Transplant WITH Conditioning (COHORT 1)\n\n1. Active, acute GvHD \\> grade II or extensive, chronic GvHD\n2. Severe life, threatening infection\n3. Pulmonary dysfunction (FEV1, FVC or DLCO 40% of predicted or 3 SD below normal)\n4. Cardiac dysfunction (LVSF less than 25%)\n5. Psychiatric disturbance\n6. Lansky or Karnofsky score \\\u003C 50%\n7. The presence of severe hepatic disease (direct bilirubin \\>3x upper limit of normal and AST \\> 5x upper limit of normal).\n8. Creatinine \\> 3x normal\n9. Known HIV Positivity\n10. Pregnancy\n\nInclusion Criteria for CD34+ Topoff WITHOUT conditioning (COHORT 2)\n\n1. Allogeneic SCT Recipient requiring additional cellular therapy\n2. Age between birth and 70 years\n3. Patient and\u002For responsible person able to understand and sign consent\n4. At least ONE of the following must be answered YES for a patient to be eligible to receive CD34+ topoff:\n\n   1. Evidence of mixed chimerisms (less than 95% donor cells)\n   2. Evidence of poor bone marrow function (bone marrow cellularity less than 50% with at least one cytopenia)\n   3. Relapsed or persistent disease\n\nExclusion criteria for CD34+ Topoff WITHOUT conditioning (COHORT 2)\n\n1. Active, acute GvHD \\> grade II or extensive, chronic GvHD\n2. Severe life, threatening infection\n3. Known HIV positivity\n4. Pregnancy\n\nInclusion Criteria for CD34+ Topoff WITH conditioning (COHORT 3)\n\n1. Allogeneic SCT Recipient requiring additional cellular therapy\n2. Age between birth and 70 years\n3. Patient and\u002For responsible person able to understand and sign consent\n4. At least ONE of the following must be answered YES for a patient to be eligible to receive CD34+ topoff:\n\n   1. Evidence of mixed chimerisms (less than 95% donor cells)\n   2. Evidence of poor bone marrow function (bone marrow cellularity less than 50% with at least one cytopenia)\n   3. Relapsed or persistent disease\n\nExclusion criteria for CD34+ Topoff WITH Conditioning (COHORT 3)\n\n1. Active, acute GVHD \\> grade II or extensive, chronic GvHD\n2. Severe life, threatening infection\n3. Pulmonary disfunction (FEV1, FVC or DLCO 40% of predicted or 3 SD below normal)\n4. Cardiac dysfunction (LVSF less than 25%)\n5. Psychiatric disturbance\n6. Lansky or Karnofsky score \\\u003C 50%\n7. The presence of severe hepatic disease (direct bilirubin \\> 3x upper limit of normal and AST \\> 5x upper limit of normal)\n8. Creatinine \\> 3x normal\n9. Known HIV positivity\n10. Pregnancy",{"count":158,"type":20},241,[23],"Participants are being asked to take part in this study because treatment of his or her disease requires a stem cell transplant. Stem cells or \"mother\" cells are the source of normal blood cells and lead to recovery of blood counts after bone marrow transplantation. Unfortunately, there is not a perfectly matched stem cell donor (like a sister or brother) for the participant and his or her disease does not permit enough time to identify another donor (like someone from a registry list that is not his or her relative) or another suitable donor has not been identified. However, a close relative of the patient has been identified whose stem cells are not a perfect match, but can be used.\n\nAlternatively, the patient may have already received a stem cell transplant but have evidence of mixed chimerism, which means some of the patient's own bone marrow cells are present, rather than all of the donor's cells. This may lead to an increased risk of the disease coming back. Or, the patient may have all donor cells but his or her bone marrow is not working very well, which may lead to frequent blood or platelet (cells that help in clotting blood) transfusions or infection.\n\nRegardless of the reason, it may be necessary to isolate stem cells from a haploidentical (half-match) donor in order to provide bone marrow function. Because the stem cells from the donor are only half-matched to the participant, the risk of graft-versus-host disease (GvHD) is very high. GvHD is a complication after transplant caused by donor T cells (graft) that attack the transplant recipient, and this complication can cause death after transplant. Thus, it is important that the donor's blood cells are treated to minimize cells that are most likely to attack the host's tissues. This is done by using a special device to capture the CD34+ stem cells from the donor's stem cell product prior to giving the cells to the host. This method minimizes the donor T cells, which are responsible for causing GvHD.\n\nPurpose: In an effort to lower the occurrences and severity of graft-versus-host disease in patients and to lower the rate of transplant failure, investigators would like to specially treat the donor's blood cells to minimize the cells that are most likely to attack the patient's tissues.",[26,162],"Allogeneic",[164,165,166],"Haploidentical Stem Cell Transplant","CD34+ Selection","CliniMACS CD34 Reagent system","2025-11-26",{"date":169,"type":36},"2025-12-03",{"date":171,"type":36},"2010-10",{"date":173,"type":20},"2027-11",{"name":175,"class":43},"Baylor College of Medicine",2,{"id":178,"slug":179,"hasResults":11,"nctId":180,"briefTitle":181,"officialTitle":182,"acronym":183,"eligibilityCriteria":184,"healthyVolunteers":11,"sex":16,"minAge":185,"maxAge":4,"enrollmentInfo":186,"targetDuration":4,"studyType":188,"phases":4,"briefSummary":189,"conditions":190,"keywords":4,"overallStatus":112,"whyStopped":4,"lastUpdateSubmitDate":196,"lastUpdatePostDateStruct":197,"startDateStruct":199,"completionDateStruct":201,"leadSponsor":203,"locationsCount":44},"100603740","monitoring-neurocognitive-dysfunction-and-the-impact-of-metabolism-and-physical-capacity-after-paediatric-hsct-100603740","NCT07140445","Monitoring Neurocognitive Dysfunction and the Impact of Metabolism and Physical Capacity After Paediatric HSCT","Monitoring Neurocognitive Dysfunction and the Impact of Metabolism and Physical Capacity After Paediatric Haematopoietic Stem Cell Transplantation (Abbreviation: MindMe)","MindMe","Inclusion Criteria:\n\n* =\u002F\\> 7 years of age\n* treatment with HSCT in Denmark since 2010\n* treatment with HSCT was before the age of 18 years\n* ability to speak and understand Danish.\n\nExclusion Criteria:\n\n* diagnosed with infantile autism before their HSCT\n* Downs Syndrome","7 Years",{"count":187,"type":20},175,"OBSERVATIONAL","Today the overall survival of childhood cancers has increased to above 85%. This increase is partially caused by treatment with bone marrow transplantation. A bone marrow transplantation is an efficient treatment against high-risk leukemia, as well as other life-threatening immunological and hematological diseases. However, it is unfortunately also related to the risk of developing a long series of late effects during early adulthood, such as reduced muscle mass, cardiovascular disease and diabetes.\n\nSome survivors of bone marrow transplantation in childhood also seem to experience changes in cognitive functions. These changes may be experienced as difficulties with concentration, forgetfulness, learning difficulties, and challenges in school or the labour market. Currently, the extent of cognitive changes following bone marrow transplantation in childhood is not fully understood, nor how it relates to other late effects, and what can be done to prevent cognitive impairment.\n\nThis research project will examine cognitive function in a group of survivors of bone marrow transplantation in childhood and find out whether there is a correlation between reduced cognitive function and the occurrence of other late effects, including metabolic changes and reduced physical capacity. It will also explore associations between cognitive function at late follow up and blood-based biomarkers of neurological damage and systemic inflammation at the time of transplantation to identify predictors of reduced cognitive function.\n\nThe goal of the study is to evaluate the level of cognitive functioning after bone marrow transplantation in childhood, see how it relates to other late effect and identify risk factors and biomarkers in the blood that can predict which patients are at risk of neurocognitive impairment. The results of this study will hopefully contribute to optimizing the prevention and treatment of cognitive impairments following bone marrow transplantation in childhood, thereby improving the quality of life for survivors of bone marrow transplantation in childhood.",[26,191,192,193,194,195],"Late Effect","Neurocognitive Dysfunction","Paediatric Patients","Metabolic Syndrome","Physical Capacity","2025-08-27",{"date":198,"type":36},"2025-09-04",{"date":200,"type":20},"2025-09-01",{"date":202,"type":20},"2027-03-01",{"name":204,"class":43},"Rigshospitalet, Denmark",{"id":206,"slug":207,"hasResults":11,"nctId":208,"briefTitle":209,"officialTitle":210,"acronym":211,"eligibilityCriteria":212,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":213,"targetDuration":4,"studyType":21,"phases":215,"briefSummary":216,"conditions":217,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":223,"lastUpdatePostDateStruct":224,"startDateStruct":226,"completionDateStruct":228,"leadSponsor":230,"locationsCount":103},"100589944","mosaic-trial-for-stem-cell-transplant-recipients-100589944","NCT06960993","Mosaic Trial for Stem Cell Transplant Recipients","Mosaic: RCT of a Digital Health Intervention for English- and Spanish-speaking Stem Cell Transplant Recipients","Mosaic","Inclusion Criteria:\n\n* Diagnosed with a hematologic cancer according to medical records\n* Scheduled for or preparing for scheduling of an allogeneic or autologous stem cell transplant at one of our study sites\n* Aged 18 or older (no upper limit)\n* English or Spanish Proficient\n* Interested in using a website to learn about stem cell transplant\n* Ability to understand and willingness to sign an informed consent document and comply with all study procedures\n\nExclusion Criteria:\n\n* Currently participating in a behavioral intervention targeting distress, health-related quality of life, or symptoms\n* Undergoing the first in a planned tandem stem cell transplant\n* Unable to provide meaningful consent (severe cognitive impairment or language difficulties)",{"count":214,"type":20},356,[23],"The goal of this clinical trial is to learn if using an intervention website (Mosaic) improves selected patient-reported outcomes in adult blood cancer patients undergoing allogeneic or autologous stem cell transplant, compared to using an educational website (control group). Patients will be recruited prior to their scheduled transplant, then randomized to use one of these two study websites throughout the study. They will complete five assessments during the study: one before transplant (baseline) and four after transplant (2, 4, 6, and 8 month follow-ups).\n\nThe main questions this trial aims to answer are:\n\n1. Compared to patients using the control group website, do patients using the intervention website report greater improvements in general psychological distress, cancer treatment-related distress, physical symptoms, and health-related quality of life?\n2. Are these benefits at least partially explained by improvements in perceived preparedness, self-efficacy, and approach coping and\u002For reductions in avoidant coping and perceived stress?\n3. Do some patients benefit more from using the intervention website than others? Specifically, we will examine whether patients' primary language (English\u002FSpanish) and their initial psychological distress are related to the benefit they get from using the intervention website. We will also explore effects of sex, race, ethnicity, and transplant type.",[218,26,60,219,220,221,222],"Hematologic Malignancy","Leukemia","Lymphoma","Multiple Myeloma","Myelodysplastic Syndromes","2025-07-17",{"date":225,"type":36},"2025-07-18",{"date":227,"type":36},"2025-04-28",{"date":229,"type":20},"2030-02-01",{"name":231,"class":43},"Northwestern University",{"id":233,"slug":234,"hasResults":11,"nctId":235,"briefTitle":236,"officialTitle":236,"acronym":237,"eligibilityCriteria":238,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":239,"targetDuration":241,"studyType":188,"phases":4,"briefSummary":242,"conditions":243,"keywords":254,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":268,"lastUpdatePostDateStruct":269,"startDateStruct":271,"completionDateStruct":273,"leadSponsor":275,"locationsCount":44},"100569332","fertility-protection-for-children-adolescents-and-young-adults-100569332","NCT06692868","Fertility Protection for Children, Adolescents and Young Adults","FeProCAYA","Children, adolescents, young adults with a diagnosis of cancer before the age of 21 years\n\nor\n\nChildren, adolescents, young adults undergoing SCT for a malignant or non-malignant condition before the age of 21 years\n\ntreated at the Department of Pediatrics and Adolescent Medicine, University Medical Center Ulm, Germany.",{"count":240,"type":20},2000,"20 Years","This study focuses on improving fertility preservation and long-term care for children, adolescents, and young adults (CAYA) undergoing cancer treatments or stem cell transplantation. These treatments can harm fertility, and ensuring that patients receive the right support and follow-up care is critical.\n\nThe main study goals are:\n\n1. Understanding Fertility Risks: Researchers aim to identify factors that predict fertility problems after cancer treatments, such as the type of therapy, hormone levels, body composition, or genetic predispositions.\n2. Addressing Patient and Family Needs: The program will explore the concerns, needs, and challenges faced by young patients and their parents regarding fertility. It will also examine how these issues affect their quality of life.\n3. Improving Clinical Care: Current practices in fertility preservation and counseling will be studied to identify gaps and improve care structures.\n\nTo achieve these goals, the program will:\n\n* Create a database to collect and analyze medical data from patients before, during, and after cancer treatments.\n* Study the prevalence and long-term effects of fertility problems in young patients.\n* Document medical interventions like fertility preservation methods (e.g., freezing eggs or sperm) and treatments for late effects.\n* Assess patients' and families' fertility-related quality of life and their informational needs.\n\nUltimately, the project aims to establish an interdisciplinary center to support fertility preservation and improve the quality of care for young patients facing cancer and its treatments.",[26,244,245,246,247,248,249,250,251,252,253],"Stem Cell Transplantation","Oncological Outcomes","Oncological Patients","Oncological Children","Fertility","Fertility Protection","Endocrinological Late-effects","Paediatric Oncology","CAYA","Survivors",[237,255,256,257,258,259,260,261,262,263,264,265,266,30,267,252],"Fertility protection","Endocrinological follow-up after oncological disease","children","fertility","adolescents","young adults","TYA","teenagers and young adults","paediatric oncology","follow-up care","endocrinological late-effects","survivors","stem cell transplantation","2025-01-13",{"date":270,"type":36},"2025-01-16",{"date":272,"type":36},"2024-12-09",{"date":274,"type":20},"2044-11",{"name":276,"class":43},"University of Ulm",{"id":278,"slug":279,"hasResults":11,"nctId":280,"briefTitle":281,"officialTitle":282,"acronym":4,"eligibilityCriteria":283,"healthyVolunteers":11,"sex":16,"minAge":284,"maxAge":17,"enrollmentInfo":285,"targetDuration":4,"studyType":21,"phases":287,"briefSummary":288,"conditions":289,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":291,"lastUpdatePostDateStruct":292,"startDateStruct":294,"completionDateStruct":296,"leadSponsor":298,"locationsCount":44},"100528009","post-transplant-ptflucy-promotes-unrelated-cord-blood-engraftment-in-haplo-cord-setting-in-childhood-leukemia-100528009","NCT06155188","Post-transplant PT\u002FFLU+CY Promotes Unrelated Cord Blood Engraftment in Haplo-cord Setting in Childhood Leukemia","A Novel Post-transplant Regimen of PT\u002FFLU+CY for Selectively Promoting Unrelated Cord Blood Engraftment in Haploidentical-cord Transplantation in Childhood Leukemia: a Single-arm, Multi-center Trial","Inclusion Criteria:\n\n* children acute leukemia\n\nExclusion Criteria:\n\n* MODS","1 Month",{"count":286,"type":20},60,[23],"To determine if the novel regimen of PT\u002FFLU+CY promotes cord blood engraftment in children's leukemia HSCT cohort",[219,26,290],"Cord Blood","2023-11-23",{"date":293,"type":36},"2023-12-04",{"date":295,"type":36},"2019-09-29",{"date":297,"type":20},"2026-12",{"name":299,"class":43},"Nanfang Hospital, Southern Medical University"]